| Literature DB >> 30064522 |
Mahmoud B Maina1,2, Laura J Bailey3, Sherin Wagih1, Luca Biasetti1, Saskia J Pollack1, James P Quinn1, Julian R Thorpe1, Aidan J Doherty3, Louise C Serpell4.
Abstract
Tau is known for its pathological role in neurodegenerative diseases, including Alzheimer's disease (AD) and other tauopathies. Tau is found in many subcellular compartments such as the cytosol and the nucleus. Although its normal role in microtubule binding is well established, its nuclear role is still unclear. Here, we reveal that tau localises to the nucleolus in undifferentiated and differentiated neuroblastoma cells (SHSY5Y), where it associates with TIP5, a key player in heterochromatin stability and ribosomal DNA (rDNA) transcriptional repression. Immunogold labelling on human brain sample confirms the physiological relevance of this finding by showing tau within the nucleolus colocalises with TIP5. Depletion of tau results in an increase in rDNA transcription with an associated decrease in heterochromatin and DNA methylation, suggesting that under normal conditions tau is involved in silencing of the rDNA. Cellular stress induced by glutamate causes nucleolar stress associated with the redistribution of nucleolar non-phosphorylated tau, in a similar manner to fibrillarin, and nuclear upsurge of phosphorylated tau (Thr231) which doesn't colocalise with fibrillarin or nucleolar tau. This suggests that stress may impact on different nuclear tau species. In addition to involvement in rDNA transcription, nucleolar non-phosphorylated tau also undergoes stress-induced redistribution similar to many nucleolar proteins.Entities:
Keywords: Alzheimer’s disease; Nucleolus, Nucleolar stress, rDNA; Tau; Tauopathy; Transcription
Mesh:
Substances:
Year: 2018 PMID: 30064522 PMCID: PMC6066928 DOI: 10.1186/s40478-018-0565-6
Source DB: PubMed Journal: Acta Neuropathol Commun ISSN: 2051-5960 Impact factor: 7.801
Fig. 1Tau localises to the nucleolus in undifferentiated and differentiated Neuroblastoma (SHSY5Y) cells. a Immunogold labelling of undifferentiated cells with T-Tau antibody using 10 nm gold particle-conjugated secondary antibody showed tau gold particles within the Nucleolus (1). Nucleus is highlighted in pink and nucleolus used in second panel is highlighted in blue. The region 1, is identified by a black box. Representative immunofluorescence fluorescence images showing colabelling for nP-Tau and FBL in undifferentiated (b) and differentiated (c) cells using Tau 1 antibody shows clear punctate distribution of nP-Tau colocalised with fibrillarin (FBL).
Fig. 2Tau localises with TIP5 and impacts on rDNA transcription and heterochromatin. Immunoprecipitation from whole cell lysates showed that tau associates with TIP5 in both undifferentiated (U.SHSY5Y) and differentiated cells (D.SHSY5Y) (ai). Double immunogold labelling revealed that Tau (15 nm) (white arrow) and TIP5 (5 nm) (black arrow) closely associate inside the nucleolus (blue) in SHSY5Y cells (see insert highlighted by black box) (aii). b Western blotting (i) and qPCR (ii) to confirm siRNA tau knockdown in undifferentiated SHSY5Y cells. ci qPCR on samples from the knockdown cells showed a significant increase in 45S-pre-rRNA synthesis (rDNA transcription), 18S rRNA and 28S rRNA processing. [45S pre-rRNA P = 0.017], [18S rRNA P = 0.018]; [28S rRNA P = 0.0038]. (cii) Western blotting shows that proteins levels of TIP5 and UBF are unchanged in tau knockdown cells. d & e Representative immunofluorescence fluorescence images showing labelling for H3K9me2/H3K9me3 control and in knockdown cells. Graphs showing quantification from four independent experiments, each with five images and each containing an average of 30 cells. Quantitative immunofluorescence labelling showed that the tau knockdown resulted in a significant reduction in the levels of H3K9me2 [P < 0.0001] (D) and number of H3K9me3 foci [P < 0.0001] (e). Labelling for 5-Methylcytosine (5-MC) showed that the tau knockdown resulted in a significant reduction in the nuclear levels of 5-mC methylation [P < 0.0001] (f). Analysis of HpaII resistance assay showed that tau knockdown reduces the T0 element methylation (g). *P < 0.05. Experiment Aii = N2. All other experiments N ≥ 4
Fig. 3Nucleolar stress co-occurs with the redistribution of nucleolar nP-Tau. a Flow cytometry experiments with CellROX Green following 20 mM Glutamate treatment of differentiated SHSY5Y showed oxidative stress [P = 0.0013]. b Western blotting analysis revealed that the glutamate treatment led to a significant decrease in TIP5, UBF, and FBL. [TIP5 P < 0.0001]; [UBF P = 0.0004]; [FBL P = 0.0002]. c qPCR analysis of rDNA transcription and processing showed that the glutamate incubation resulted in a significant decrease in 45S pre-rRNA synthesis [45S pre-rRNA P = 0.008]. d Representative immunofluorescence fluorescence images showing labelling for nP-Tau and FBL control and following glutamate treatment (Arrows showing regions in which colocalisation of nP-Tau and FBL is altered by Glutamate treatment). Graphs showing quantification from four independent experiments each with five images and each containing an average of 35 cells. Glutamate administration resulted in redistribution of nucleolar nP-Tau from FBL (blue arrow), as well as FBL redistribution from nP-Tau (white arrows) compared to the control. Analysis of immunofluorescence reveals a significant increase in the number (33%) of cells showing FBL redistribution (dii) [P < 0.02]. Quantification revealed that 14% of Glutamate-treated cells showed nucleolar nP-Tau redistribution (diii). [P < 0.02]. Total level of nuclear nP-Tau is increased (div) [P < 0.001]. dv Western blotting on whole cell extracts showed a significant increase in nP-Tau, with no changes in T-Tau levels. nP-Tau [P < 0.0001]; T-Tau: [P = 0.47]. Intensity normalised to β-actin. Images showing nucleolar tau and FBL in untreated and treated cells were Z-projected for maximum intensity. For all experiments N ≥ 4
Fig. 4Cellular stress induces nuclear accummulation of P-Tau which does not colocalise with nucleolar markers. Representative immunofluorescence fluorescence images showing labelling for P-Tau and T-Tau control and following glutamate treatment. Graphs show quantification from four independent experiments, each with five images and each containing an average of 40 cells. Immunofluorescence microscopy showed a significant increase in nuclear levels of P-Tau (a) and T-Tau (b). T-Tau: [P < 0.0001] and P-Tau: [P < 0.0001]. Double labelling revealed that the nuclear P-Tau does not colocalise with FBL (c) or nP-Tau (d). N ≥ 4
Fig. 5Immunogold electron microscopy to localise tau in the human brain neuronal nucleus. Brain sections labelled with T-Tau (10 nm gold) showed the presence of tau in the (ai) nucleus and nucleolus (circle in blue) (aii). Double immunogold labelling for Tau 1 (nP-Tau) (15 nm) (white arrows) and TIP5 (5 nm) (black arrows) showed that they associate in neuronal nucleolus in human brain (bi zoomed in bii, see insert for labelling in the nucleolus and nucleolar border). Representative images are shown. Single labelling experiments (a) were conducted on sections from two human cases, while double labelling (b) was conducted on three cases. For both single and double labelling, four grids were taken from each case, from which four nuclei per grid of medium to large size were randomly selected and imaged